Tag: ESC 2025
Cardiovascular News – Issue 79 – November 2025 (US)
In this issue:
Get up to date on late-breaking trials from the Transcatheter Cardiovascular The...
Cardiovascular News – Issue 79 – November 2025 (OUS)
In this issue:
Get up to date on late-breaking trials from the Transcatheter Cardiovascular The...
Intensive cholesterol lowering fails to shift the dial on vein graft failure
Intensive LDL cholesterol lowering with evolocumab does not reduce saphenous vein graft failure ...
Medtech Insights: Edwards’ Brüls outlines company’s move to specialise on structural heart disease
When Cardiovascular News sits down with Annette Brüls at the 2025 European Society of Cardiology...
Timing DAPT based on risk score may reduce risk of adverse events
Tailoring dual antiplatelet therapy (DAPT) for patients who have undergone percutaneous coronary...
ESC 2025: AQUATIC trial cautions against use of aspirin in chronic coronary syndrome patients receiving anticoagulation
New evidence cautions against the use of aspirin in patients with chronic coronary syndrome who ...
ESC 2025 hears long-term data from DANGER-SHOCK trial
Routine use of the Impella CP (Abiomed) micro-axial flow pump in the treatment of patients with ST-s...
ESC 2025: Studies shed new light on antiplatelet therapy after CABG surgery
New evidence offers fresh insights into the merits of dual antiplatelet therapy (DAPT) following...
ESC 2025: Baxdrostat shows promise in lowering blood pressure in uncontrolled and resistant hypertension
Results from the BaxHTN phase III trial showed baxdrostat (AstraZeneca)—a highly selective aldoste...
ESC 2025: DUAL-ACS trial finds “less is more” for DAPT after acute MI
A three-month course of dual antiplatelet therapy (DAPT) after an acute myocardial infarction (M...
SWEDEPAD re-opens paclitaxel safety discussion, finds drug-coated devices do not improve outcomes
Drug-coated balloons and stents were not associated with reduced risk of amputation or improved ...
ESC 2025: REBOOT prompts rethink on use of beta blockers in uncomplicated MI
Beta-blocker therapy appeared to be ineffective at reducing death, reinfarction or hospitalisation f...
ESC 2025: Trial results add digitoxin as an option for patients with advanced heart failure
Digitoxin reduced the risk of a composite of all-cause death and hospitalisation for worsening h...
Roxana Mehran receives ESC Gold Medal
Roxana Mehran (Icahn School of Medicine at Mount Sinai, New York, USA) was presented with the to...
ESC 2025: Guideline revisions include new TAVI age threshold
Latest randomised trial evidence has contributed to new joint guidelines from the European Socie...
Navitor TAVI valve picks up expanded CE mark for low-risk patients
Abbott’s Navitor transcatheter aortic valve implantation (TAVI) system has received CE mark for the ...
ESC 2025: “Minimalist” approach to TAVI may be an option for most patients
A “minimalist” transcatheter aortic valve implantation (TAVI) strategy—using local anaesthesia w...
